CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (PHGRF) (PHGI), Acasti Pharma Inc (ACST), Atossa Genetics Inc (ATOS), and Verastem Inc (VSTM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.
Premier Health Group (PHGRF) (PHGI) opened Wednesday with the Company's shares trading at $0.60 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month. In December, the Company announced that, as a means of furthering their efforts to develop innovative approaches that combine human-skill based expertise with emerging technologies for the healthcare sector, it had signed a binding letter of intent to acquire all outstanding securities of Cloud Practice Inc.
Presently, Cloud Practice offers cloud-based electronic medal records software for medical professionals across Canada. As stated in their recent financial reports, Cloud Practice is EBITDA positive, resulting in immediate cash flow generation and earnings accretion for Premier Health.
In affirmation of the LOI, Premier Health Group (PHGRF) (PHGI)'s CEO, Dr. Essam Hamza, said, "We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system."
Acasti Pharma Inc (ACST) found itself in headlines today after the biopharmaceutical company announced a Certificate for a European Patent had been issued by the European Patent Office. The granted patent is valid until 2030 and relates to a concentratedphospholid composition and method of using the same for modulating blood lipids.
Pierre Lemieux, COO and CSO of Acasti, commented, "This is an important milestone for Acasti, as the allowance of a patent in a major jurisdiction such as Europe further strengthens and expands the Company's intellectual property portfolio. This patent contains broadclaims, and provides us now with uniform protection across all major markets in Europe. Furthermore, it strengthens the Company's strategic position, which could support valuable commercial opportunities for the Company."
Atossa Genetrics Inc (ATOS), a clinical-stage biopharmaceutical company purposed with developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported final results from its Phase 1 dose-escalation study of its newest topical drug treatment for male subjects.
In a press release regarding the announcement, Dr. Steven C. Quay, CEO and President of Atossa, said, "These positive final results support the further development of topical Endoxifen to treat breast health conditions in men, including a condition called gynecomastia, or breast enlargement and pain, which frequently occurs in men taking androgen deprivation therapy for prostate cancer. We are also conducting a Phase 2 study using our topical Endoxifen in women with mammographic breast density (MBD) which we anticipate completing in the secondquarter 2019."
For More Information on Atossa Genetics, Inc, Click HereVerastem, Inc (VSTM), a company focused on developing and commercializing treatments to improve those suffering from cancer, announced earlier this week the grant of options to purchase 19,467 shares of common stock to three new employees and 22,200 restricted stock units to one new employee. Per the announcement, the awards weregradated asinducement material to the employees' acceptance of employment with the company.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid "500,000" shares of restricted common shares (as of 1/9/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.